rhinoplasty.cc
Menu

Journal archive · 2020

FPSAM Facial Plastic Surgery and Aesthetic Medicine · 2020

The Efficacy of Oral Celecoxib Following Surgical Rhinoplasty

Newberry CI, McCrary HC, Cerrati EW.

What this paper says

Among 51 rhinoplasty patients, the 17 given celecoxib took a mean 4.2 opioid tablets versus 14.8 in controls, a 76.2 percent reduction in opioid milligrams and an 83.4 percent reduction in nausea and vomiting.

Overview

Reducing opioid use after surgery is a stated priority, and non-narcotic alternatives are one route. This prospective cohort study compared patients who received celecoxib, an anti-inflammatory that does not increase bleeding risk in the way older ones do, against those who did not.

Sections of note

  • Prospective cohort of 51 consecutive patients who had rhinoplasty between July 2018 and May 2019 by a single facial plastic surgeon.
  • A questionnaire on pain medication use and complications was given at the 1-week postoperative visit; patients were grouped by whether celecoxib was used.
  • 17 of the 51 patients received celecoxib.
  • Mean oxycodone-acetaminophen tablets: 4.2, CI 2.4 to 6.1, versus 14.8 in controls, CI 11.1 to 18.4, p 0.0006.
  • Mean oxycodone-acetaminophen dose: 17.6 mg, CI 9.0 to 26.3, versus 73.8 mg, CI 55.5 to 92.0, p 0.0001.
  • Mean total oral morphine equivalents: 26.5, CI 13.5 to 39.4, versus 110.7, CI 83.3 to 138.0, p 0.001.
  • Nausea and vomiting were significantly reduced, p 0.02; overall a 76.2 percent decrease in opioid milligrams and 83.4 percent decrease in nausea and vomiting, without increased surgical complications. Level of evidence 2.

What it means for a patient

  • Adding a non-opioid anti-inflammatory reduced opioid use by roughly three quarters.
  • Nausea and vomiting, which are largely opioid side effects, fell correspondingly.
  • No increase in surgical complications such as bleeding was reported.
  • Limits: 51 patients with only 17 in the treatment group, not randomized, one surgeon, and medication use self-reported at one week.

Why this paper matters

Opioid prescribing after rhinoplasty consistently exceeds what patients need, and a drug that displaces most of it addresses that directly. The effect size here is large. The non-randomized design with a small treatment group means the size of the true effect is uncertain.

Terms

  • Celecoxib: An anti-inflammatory painkiller that selectively blocks COX-2.
  • Oxycodone-acetaminophen: A common combination tablet of an opioid and paracetamol.
  • Oral morphine equivalent: A standard unit allowing different opioids to be compared by strength.
  • Prospective cohort: A group tracked forward in time as events occur.
  • Perioperative: Around the time of the operation.

Summary written by rhinoplasty.cc from the abstract, 2026-09-09; not medical advice. The authors' own abstract follows.

From the abstract

“Exploring potential methods of controlling postoperative rhinoplasty pain with non-narcotic medications. Objective: To examine the effects of celecoxib in reducing pain and possible opioid consumption after rhinoplasty surgery. Design, Setting, and Participants: This is a prospective cohort study of 51 consecutive…”

Excerpt; the full abstract is on PubMed.

Citation

PubMed
Journal
Facial Plastic Surgery and Aesthetic Medicine
Year
2020
Authors
3
Type
Clinical Trial, Journal Article
Access
Subscription
On this site
Summary and abstract

Start here

This paper sits outside the 16 topic groups; the archive holds every paper by journal and year.

Related papers

Same journal, 2020.

  1. FPSAM
    2020PMID 32130066Summary
  2. FPSAM
    2020PMID 32053419Summary
  3. FPSAM
    2020PMID 32053420
  4. FPSAM
    2020PMID 32212975
  5. FPSAM
    2020PMID 32380871Summary
  6. FPSAM
    2020PMID 32223570Summary
  7. FPSAM
    2020PMID 32628569Summary
  8. FPSAM
    2020PMID 32749869